- Q2-2018 ·
Frost & Sullivan Independent Equity Research
RedHill Biopharma Ltd.: The Strategic Expansion and Clinical Progress are in line with the Company’s plans. Stock Target Price Unchanged.
Company: RedHill Biopharma Ltd.
Report type: Quarterly Report
Published on: August 8th, 2017
RedHill research articles:
All articles loaded
No more articles to load